Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL734829 | 0.92 | POLB (0.36) | SMN1; SMN2POLBHTR7NOTUMSMYD2 | |
| SCHEMBL734902 | 0.87 | HSD17B10 (0.38) | SMN1; SMN2LMNAPOLBNOTUMALDH1A1 | |
| SCHEMBL734524 | 0.77 | NOTUM (0.36) | NOTUM | |
| SCHEMBL735209 | 0.77 | POLB (0.44) | SMN1; SMN2LMNAPOLBHTR7NOTUM | |
| SCHEMBL734745 | 0.73 | HTR7 (0.39) | SMN1; SMN2LMNAPOLBHTR7HSD17B10 | |
| SCHEMBL734746 | 0.73 | HTR7 (0.39) | SMN1; SMN2LMNAPOLBHTR7HSD17B10 | |
| SCHEMBL734727 | 0.72 | HSD17B10 (0.45) | SMN1; SMN2LMNAPOLBHTR7NOTUM | |
| SCHEMBL733294 | 0.72 | HTR7 (0.40) | SMN1; SMN2LMNAPOLBHTR7ALDH1A1 | |
| SCHEMBL734643 | 0.68 | HSD17B10 (0.44) | SMN1; SMN2LMNAPOLBHTR7ALDH1A1 | |
| SCHEMBL736706 | 0.68 | HTR7 (0.37) | LMNAPOLBHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138175-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022518-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR5 | SMN1; SMN2 4455/4885LMNA 3760/4885POLB 4167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.